Bispecific T-cell engagers (BiTE)

Bispecific T-cell engagers (BiTEs) represent a groundbreaking class of immunotherapeutic agents that function as synthetic antibody constructs, designed to redirect and activate T cells to kill tumor cells by bringing them into close proximity with cancer-associated antigens. BiTEs are a subset of bispecific antibodies (bsAbs), with unique pharmacodynamic properties and highly specific targeting capability, particularly in hematologic malignancies and increasingly in solid tumors.

---

1. Molecular Structure and Design

Bispecific T-cell engagers (BiTEs) are engineered proteins that consist of two single-chain variable fragments (scFv) derived from monoclonal antibodies:

• One scFv targets CD3ε, a component of the T-cell receptor (TCR) complex on cytotoxic T lymphocytes.

• The other scFv targets a tumor-associated antigen (TAA), such as CD19 on B cells.

These scFv domains are linked via a flexible peptide linker, forming a bi-functional single-chain antibody with a total molecular weight of approximately 55–60 kDa. Unlike traditional full-size bispecific antibodies, BiTEs lack an Fc region, which contributes to their small size and rapid tissue penetration but also results in a shorter half-life.

---

2. Mechanism of Action

BiTEs act by physically connecting T cells to cancer cells, enabling immune-mediated cytotoxicity independent of antigen presentation or co-stimulation.

Steps in the BiTE mechanism:

1. Engagement of CD3 on T cells activates them non-specifically, bypassing the need for antigen specificity.

2. Binding to TAA on tumor cells brings activated T cells into direct contact with the malignant cells.

3. Formation of an immunological synapse, mimicking natural cytolytic interactions.

4. Perforin and granzyme release by cytotoxic T cells induces apoptosis of the tumor cell.

5. T cells are then recycled and redirected to engage other tumor cells in a serial-killing mechanism.

This approach is:

• HLA-independent

• MHC-unrestricted

• Capable of eradicating low tumor burden residual disease

---

3. Approved BiTE Therapeutics

Blinatumomab (Blincyto) – First and only FDA-approved BiTE (as of 2024)

• Target: CD19 (B cells) × CD3 (T cells)

• Approved Indications:

  • B-cell precursor acute lymphoblastic leukemia (ALL), relapsed/refractory (R/R)

  • Minimal residual disease (MRD)-positive B-cell ALL

• FDA Approval: 2014 (accelerated approval), 2017 (full approval)

• Formulation: Continuous IV infusion due to short half-life (~2 hours)

• Dose: Varies by indication; stepwise dosing to mitigate CRS risk

---

4. BiTEs in Clinical Development

Numerous BiTE molecules are in clinical trials, targeting a wide range of malignancies:

A. Hematologic Targets:

• CD20×CD3 BiTEs:

  • Mosunetuzumab (FDA-approved as a bispecific antibody, not classic BiTE)

  • Glofitamab

• BCMA×CD3 BiTEs:

  • AMG 420

  • Teclistamab (FDA-approved as a full bsAb)

• CD123×CD3:

  • Flotetuzumab – Acute myeloid leukemia (AML)

• CD33×CD3:

  • AMG 330 – AML

B. Solid Tumor Targets:

• EpCAM×CD3: Solitomab – Advanced epithelial cancers

• CEA×CD3: Cibisatamab – Colorectal cancer

• PSMA×CD3: AMG 160 – Prostate cancer

• HER2×CD3: GBR1302 – HER2+ solid tumors

These agents vary structurally; some incorporate half-life extension strategies (e.g., Fc fusion) or additional co-stimulatory domains.

---

5. Clinical Indications and Emerging Areas

Established Indications (FDA-approved):

• Relapsed/refractory B-cell precursor ALL (blinatumomab)

• MRD-positive B-ALL

Clinical Trials for:

• Non-Hodgkin lymphomas (e.g., DLBCL, FL)

• Multiple myeloma

• AML and high-risk MDS

• Solid tumors (lung, breast, prostate, colorectal)

Potential Expansion Areas:

• First-line therapy in combination with chemotherapy

• Post-CAR T cell relapse

• Bridging therapy prior to HSCT (hematopoietic stem cell transplantation)

---

6. Administration and Dosing

Blinatumomab:

• Administered as continuous IV infusion over 28 days per cycle

• Requires hospitalization during the first 9 days of cycle 1 due to CRS and neurotoxicity risks

• Dosing: Step-up regimen (e.g., 9 µg/day for 7 days, then 28 µg/day)

• Requires premedication with dexamethasone

Other BiTEs (in trials):

• Half-life extended BiTEs allow for weekly or biweekly dosing (e.g., AMG 160, AMG 701)

• Subcutaneous formulations under investigation

---

7. Adverse Effects

BiTE therapies are associated with unique immune-mediated toxicities due to robust T-cell activation.

A. Cytokine Release Syndrome (CRS):

• Most common and potentially life-threatening

• Fever, hypotension, hypoxia, transaminitis

• Graded per ASTCT criteria

• Managed with:

  • IL-6 receptor antagonist (e.g., tocilizumab)

  • Corticosteroids

  • Step-up dosing and hospitalization for initial dosing

B. Neurotoxicity (ICANS – immune effector cell-associated neurotoxicity syndrome):

• Headache, confusion, seizures, encephalopathy

• More common in ALL patients

• Typically reversible with supportive care and steroids

C. Other adverse effects:

• Infections (especially opportunistic)

• Cytopenias (neutropenia, anemia, thrombocytopenia)

• Hypogammaglobulinemia

• Infusion reactions

---

8. Contraindications and Precautions

Absolute Contraindications:

• Known hypersensitivity to BiTE components

• Life-threatening CRS or ICANS (for rechallenge)

Relative Contraindications:

• Uncontrolled active infections

• Severe baseline neurological disorders

• Pre-existing CNS leukemia (relative for blinatumomab)

Precautions:

• Premedication with corticosteroids

• Close monitoring for CRS and ICANS

• Hospitalization during initial dosing

• Interrupt therapy for Grade ≥2 toxicities

• Monitor B-cell aplasia and infection risk

---

9. Immunogenicity

As protein biologics, BiTEs carry the risk of anti-drug antibody (ADA) formation. However:

• Blinatumomab has low immunogenicity (~1–5%)

• Humanization of antibody fragments reduces ADA generation

• ADAs may neutralize efficacy or cause hypersensitivity reactions

---

10. Pharmacokinetics

Blinatumomab (classic BiTE):

• Low molecular weight (~55 kDa)

• No Fc region → short half-life (~2 hours)

• Requires continuous infusion (CIV) via ambulatory pump

• Rapid clearance

BiTEs with half-life extension (e.g., AMG 701):

• Fc fusion or PEGylation to extend dosing interval

• Subcutaneous or intermittent IV dosing

• Enhanced outpatient convenience

---

11. Resistance Mechanisms

Resistance to BiTEs may arise due to:

• Downregulation or loss of target antigen (e.g., CD19-negative relapse)

• T-cell exhaustion or senescence

• Immunosuppressive tumor microenvironment (TME)

• Soluble forms of target antigen acting as decoys

Strategies to overcome resistance include:

• Targeting alternative or dual antigens (e.g., CD20/CD19)

• Combining with immune checkpoint inhibitors (PD-1 blockade)

• Modifying TME (e.g., IL-15 agonists, oncolytic viruses)

---

12. Comparison with Other Immunotherapies

Therapy Type	Example	Mechanism	Key Features
BiTE	Blinatumomab	T cell redirection via CD3/TAA	Continuous IV, short half-life
CAR T-cell Therapy	Tisagenlecleucel	Autologous modified T cells	Personalized, high efficacy, high toxicity
Checkpoint Inhibitors	Pembrolizumab	PD-1/PD-L1 or CTLA-4 blockade	Releases T-cell suppression
ADCs	Brentuximab vedotin	Monoclonal Ab + cytotoxic payload	Direct tumor cell killing

13. Future Directions and Research

• Dual-targeting BiTEs to reduce antigen escape

• Tumor-infiltrating BiTEs designed to activate T cells only within tumor microenvironment

• Off-the-shelf subcutaneous BiTEs with longer half-life

• BiTEs with immune checkpoint modulation

• Application to solid tumors remains a major frontier under exploration